Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Exscientia

    - PMLiVE

    AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

    Around one in five breast cancer cases are HER2-positive

    - PMLiVE

    Medicus Pharma completes patient enrolment for basal cell carcinoma trial

    Interim results have shown over 60% clinical clearance in patients treated with SkinJect

    - PMLiVE

    Researchers at University of Geneva develop test platform for cancer treatments

    The new platform could speed up testing while reducing the need for animal models

    Amiculum's Aaron Fletcher smiling to camera on the left, with text on the right that reads 'AI persona generation'

    AI persona generation for healthcare: quick wins & real-world impact

    By Aaron Fletcher

    Amiculum

    VuuAI and Amiculum

    VuuAI and Amiculum partner to transform content engagement in pharma

    Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation platform. The collaboration is designed to optimize the deployment of...

    Amiculum

    - PMLiVE

    Does real-world use of AI in systematic literature reviews result in time and cost savings?

    By Manca Povsic and Emma Griffiths

    Amiculum

    - PMLiVE

    Inizio launches InConcert™ to transform pre-launch planning through connected intelligence.

    Inizio today announced the launch of InConcert™, a new AI-powered data solution designed to accelerate smarter, evidence-led decisions during the critical pre-launch phase of the product lifecycle.

    Inizio

    - PMLiVE

    Merck agrees deal with Cidara Therapeutics worth almost $9.2bn

    Cidara’s long-acting viral flu drug showed significant protection in phase 2 results

    - PMLiVE

    Merck ends development agreement with Dr Falk Pharma for monoclonal antibody

    Merck will take full control of developing MK-8690, an investigational monoclonal antibody candidate

    - PMLiVE

    Merck and Blackstone agree on funding for cancer protein antibody

    The funding will support late-stage clinical development of the investigational antibody-drug conjugate

    - PMLiVE

    Ipsen to acquire ImCheck Therapeutics in a deal worth up to €1bn

    The acquisition includes a clinical stage acute myeloid leukaemia treatment currently in phase 1/2 trials

    - PMLiVE

    David Weinreich appointed as Merck’s head of R&D and CMO for healthcare

    Weinreich brings clinical development and venture capital experience to the role

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links